Cargando…

Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment

Hemolytic uremic syndrome is defined by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli O157:H7. Common vehicles of transmission include...

Descripción completa

Detalles Bibliográficos
Autores principales: Boyer, Olivia, Niaudet, Patrick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159990/
https://www.ncbi.nlm.nih.gov/pubmed/21876803
http://dx.doi.org/10.4061/2011/908407
_version_ 1782210506527866880
author Boyer, Olivia
Niaudet, Patrick
author_facet Boyer, Olivia
Niaudet, Patrick
author_sort Boyer, Olivia
collection PubMed
description Hemolytic uremic syndrome is defined by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli O157:H7. Common vehicles of transmission include ground beef, unpasteurized milk, and municipal or swimming water. Shiga-toxin-associated HUS is a main cause of acute renal failure in young children. Management remains supportive as there is at present no specific therapy to ameliorate the prognosis. Immediate outcome is most often favourable but long-term renal sequelae are frequent due to nephron loss. Atypical HUS represents 5% of cases. In the past 15 years, mutations in complement regulators of the alternative pathway have been identified in almost 60% of cases, leading to excessive complement activation. The disease has a relapsing course and more than half of the patients either die or progress to end-stage renal failure. Recurrence after renal transplantation is frequent.
format Online
Article
Text
id pubmed-3159990
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-31599902011-08-29 Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment Boyer, Olivia Niaudet, Patrick Int J Nephrol Review Article Hemolytic uremic syndrome is defined by the characteristic triad of microangiopathic hemolytic anemia, thrombocytopenia, and acute renal failure. In children, most cases of HUS are caused by Shiga-toxin-producing bacteria, especially Escherichia coli O157:H7. Common vehicles of transmission include ground beef, unpasteurized milk, and municipal or swimming water. Shiga-toxin-associated HUS is a main cause of acute renal failure in young children. Management remains supportive as there is at present no specific therapy to ameliorate the prognosis. Immediate outcome is most often favourable but long-term renal sequelae are frequent due to nephron loss. Atypical HUS represents 5% of cases. In the past 15 years, mutations in complement regulators of the alternative pathway have been identified in almost 60% of cases, leading to excessive complement activation. The disease has a relapsing course and more than half of the patients either die or progress to end-stage renal failure. Recurrence after renal transplantation is frequent. SAGE-Hindawi Access to Research 2011 2011-08-17 /pmc/articles/PMC3159990/ /pubmed/21876803 http://dx.doi.org/10.4061/2011/908407 Text en Copyright © 2011 O. Boyer and P. Niaudet. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Boyer, Olivia
Niaudet, Patrick
Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment
title Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment
title_full Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment
title_fullStr Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment
title_full_unstemmed Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment
title_short Hemolytic Uremic Syndrome: New Developments in Pathogenesis and Treatment
title_sort hemolytic uremic syndrome: new developments in pathogenesis and treatment
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3159990/
https://www.ncbi.nlm.nih.gov/pubmed/21876803
http://dx.doi.org/10.4061/2011/908407
work_keys_str_mv AT boyerolivia hemolyticuremicsyndromenewdevelopmentsinpathogenesisandtreatment
AT niaudetpatrick hemolyticuremicsyndromenewdevelopmentsinpathogenesisandtreatment